Alcon Entering Refractive Laser Surgery Market Via $890 Mil. Summit Buy
This article was originally published in The Gray Sheet
Executive Summary
Alcon Labs' $890 mil. cash purchase of ophthalmic excimer laser manufacturer Summit Autonomous will place it on a level playing field with competitor Bausch & Lomb, which already competes in the eye laser market. The definitive deal was announced May 26.
You may also be interested in...
Alcon LADARWave Will Be First “Custom” LASIK PMA To Reach Panel
Alcon's LADARWave in-situ keratomileusis (LASIK) wavefront laser system will be the first "custom LASIK" system to reach FDA panel review, according to the company. The agency's 1Ophthalmic Devices Advisory Panel will review the firm's PMA at its Aug. 1 meeting in Gaithersburg, Maryland
Alcon LADARWave Will Be First “Custom” LASIK PMA To Reach Panel
Alcon's LADARWave in-situ keratomileusis (LASIK) wavefront laser system will be the first "custom LASIK" system to reach FDA panel review, according to the company. The agency's 1Ophthalmic Devices Advisory Panel will review the firm's PMA at its Aug. 1 meeting in Gaithersburg, Maryland
Alcon's Summit Buy Highlights Increasing Consolidation In Ophthalmic Sector
Alcon Labs' recent decision to purchase Summit Autonomous signals a wider trend of consolidation in the ophthalmic device arena, a sector often dismissed by the investment community in recent years as lacking high-growth potential.